Anatomical Femoral Stem in Total Hip Arthroplasty

NCT ID: NCT04243980

Last Updated: 2020-01-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-02-01

Study Completion Date

2022-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A study that detect the femoral anteversion after total hip arthroplasty using short anatomical femoral stem compared to the contrast side

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Patient Compliance Patient Satisfaction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

Patients after total hip arthroplasty with short femoral stem

Short anatomical femoral stem in THR

Intervention Type DEVICE

Patients with osteoarthritis after total hip arthroplasty

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Short anatomical femoral stem in THR

Patients with osteoarthritis after total hip arthroplasty

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age 18-90
* patients who had THR as an elective surgery
* patients who had THR with short femoral anatomical stem

Exclusion Criteria

* severe osteoporosis with Dorr C classification
* s/p bilateral hip arthroplasty
* non-complaint patients
* revision surgery
Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

HaEmek Medical Center, Israel

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Raja Hakim

Medical Doctor

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Raja Hakim, M.D.

Role: CONTACT

00972546612251

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EMC-19-0100

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Exception Cementless Hip Stem
NCT04349046 ACTIVE_NOT_RECRUITING